Elite in Oligodendroglioma

Dr. John F. De Groot

Neurology
Ucsf Medical Group Business Services
521 Parnassus Ave, 
San Francisco, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Elite in Oligodendroglioma
Ucsf Medical Group Business Services
521 Parnassus Ave, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John De Groot is a Neurologist in San Francisco, California. Dr. De Groot is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

His clinical research consists of co-authoring 193 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 9 articles in the study of Oligodendroglioma.

Specialties
Neurology
Licenses
Psychiatry & Neurology in TX
Hospital Affiliations
Ucsf Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Valley Health
  • HMO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 12 Less Insurance Carriers -

Locations

UCSF MEDICAL GROUP BUSINESS SERVICES
521 Parnassus Ave, San Francisco, CA 94143
Other Locations
UCSF MEDICAL GROUP BUSINESS SERVICES
3100 San Pablo Ave, Berkeley, CA 94702

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Radiation, Biological
Study Drugs: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Study Phase: Phase 2/Phase 3
Phase I Trial of DNA-PK Inhibitor (M3814) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated Glioblastoma
Phase I Trial of DNA-PK Inhibitor (M3814) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated Glioblastoma
Enrollment Status: Recruiting
Publish Date: July 23, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Nedisertib, Temozolomide
Study Phase: Phase 1
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Telaglenastat Hydrochloride, Temozolomide
Study Phase: Phase 1
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
Enrollment Status: Completed
Publish Date: March 24, 2025
Intervention Type: Drug
Study Drug: Paxalisib (GDC-0084)
Study Phase: Phase 2
Phase I/Ib Study of Sarasar and Temodar in Patients with Recurrent or Temodar-Refractory Glioblastoma Multiforme
Phase I/Ib Study of Sarasar and Temodar in Patients with Recurrent or Temodar-Refractory Glioblastoma Multiforme
Enrollment Status: Active_not_recruiting
Publish Date: October 17, 2024
Intervention Type: Drug
Study Drugs: Lonafarnib, Temozolomide
Study Phase: Phase 1
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Biological, Other, Drug
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 1
A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: September 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

194 Total Publications

Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical Trial.
Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical Trial.
Journal: JAMA oncology
Published: June 18, 2025
Similar Doctors
Elite in Oligodendroglioma
Dr. Jennie Taylor
Neurosurgery | Neurology
Elite in Oligodendroglioma
Dr. Jennie Taylor
Neurosurgery | Neurology

Ucsf Medical Group Business Services

400 Parnassus Ave, A808, 
San Francisco, CA 
 (0.1 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jennie Taylor is a Neurosurgery specialist and a Neurologist in San Francisco, California. Dr. Taylor is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. Her top areas of expertise are Glioma, Astrocytoma, Brain Tumor, and Glioblastoma.

Distinguished in Oligodendroglioma
Dr. Jennifer L. Clarke
Neurology | Neurosurgery
Distinguished in Oligodendroglioma
Dr. Jennifer L. Clarke
Neurology | Neurosurgery

Ucsf Medical Group Business Services

505 Parnassus Ave, M1490, 
San Francisco, CA 
 (0.1 miles away)
415-472-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jennifer Clarke is a Neurologist and a Neurosurgery provider in San Francisco, California. Dr. Clarke is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. Her top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Gliomatosis Cerebri.

Distinguished in Oligodendroglioma
Dr. Lawrence Recht
Neurology
Distinguished in Oligodendroglioma
Dr. Lawrence Recht
Neurology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (27.6 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lawrence Recht is a Neurologist in Stanford, California. Dr. Recht is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. De Groot's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 8 Distinguished Conditions
View All 7 Advanced Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile